AbbVie
Clinical trials sponsored by AbbVie, explained in plain language.
Global biopharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo shows promise in early cancer trial Results expected Sep 2026 (estimated)
- New drug bretisilocin tested in healthy volunteers for first time Results expected Sep 2026 (estimated)
- Healthy volunteers needed for drug interaction study Results expected Sep 2026 (estimated)
- Real-world study tracks how IBD treatment goals are met in clinics worldwide Results expected Sep 2026 (estimated)
- New hope for kids with joint pain: risankizumab trial launches Results expected Sep 2026 (estimated)
-
Antibody-Drug conjugate takes aim at c-Met-High lung cancer
Disease control Not yet recruitingResearchers are testing whether an experimental drug called telisotuzumab adizutecan works better than standard chemotherapy for people with non-squamous non-small cell lung cancer that has grown after earlier treatment. The trial enrolls about 660 participants whose tumors are E…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new injection outperform standard care for a rare protein disease?
Disease control Not yet recruitingThis phase 3 trial compares an investigational drug called etentamig against a standard combination therapy (daratumumab, cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. Abo…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new drug combo outperform standard therapy for lung cancer?
Disease control Not yet recruitingThis phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted drug combo outsmart advanced head and neck cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to the standard immunotherapy pembrolizumab can better control recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls adults whose tumors express a speci…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a pill outperform biologics for severe eczema?
Disease control Not yet recruitingThis study looks at how well upadacitinib, a daily pill, works compared to biologic injections for people with moderate-to-severe atopic dermatitis (eczema). The goal is to see if more patients can reach a state of minimal disease activity, meaning nearly clear skin and little to…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new drug combo outsmart Hard-to-Treat myeloma?
Disease control Not yet recruitingThis phase 3 trial is testing whether an experimental drug called etentamig, combined with pomalidomide, can control multiple myeloma that has come back or stopped responding to treatment. About 520 adults who have already tried 1 to 3 prior therapies will be randomly assigned to…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Real-World study tests migraine prevention pill in UK clinics
Disease control Not yet recruitingThis study looks at how well atogepant, a daily pill, works to prevent migraines in adults treated in UK primary care. About 200 people with migraine will take atogepant as prescribed by their doctor and report their symptoms and healthcare use for up to 48 weeks. The goal is to …
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Real-World check: targeted drug MIRV tested against tough ovarian cancer
Disease control Not yet recruitingThis study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can cosmetic injections boost confidence in jawline and neck?
Symptom relief Not yet recruitingThis study tests whether injections of BOTOX and Juvéderm fillers can improve how people feel about their jawline and neck. Participants with moderate to severe neck lines, loss of jawline definition, or prominent neck bands will receive the injections. Researchers will measure s…
Phase 4 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC